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SENSITIVITY
AND
SPECIFICITY
OF
INTRATHECAL FLUORESCEIN AND WHITE
LIGHT EXCITATION FOR DETECTING
INTRAOPERATIVE CEREBROSPINAL FLUID
LEAK IN ENDOSCOPIC SKULL BASE
SURGERY: A PROSPECTIVE STUDY[2]
Study Question: What is the diagnostic value of
intrathecal fluorescein to identify an intraoperative
cerebrospinal fluid (CSF) leak during endoscopic
endonasal skull base surgery?
The authors review a prospectively accrued database
of consecutive patients to assess the effectiveness of
the off‑label routine use of intrathecal fluorescein to
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detect an intraoperative cerebrospinal fluid (CSF) leak
during endoscopic endonasal skull base surgery. Patients
were pretreated with intravenous dexamethasone and
diphenhydramine prior to administration of 25 mg
of fluorescein injected immediately before surgery via
lumbar puncture or lumbar drain. Basic white light
illumination from the endoscope was used to identify
the presence of unstained or fluorescein‑tinged CSF
during the procedure. A dural reconstruction algorithm
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developed by the authors, based on leak severity and
location/size of the skull base defect, was used for skull
base reconstruction. A valsalva maneuver was then
performed to assess reconstruction integrity and ensure
no visualization of fluorescein at the conclusion of the
procedure. Temporary postoperative CSF drainage was
performed with duration dependent on the treated
pathology. Lesion type and location, endonasal approach
corridor, reconstruction method, operative time, and
presence of postoperative CSF leak were analyzed.
A total of 419 patients were included in this study over
nearly a 10‑year period at a single institution. Of 269
patients who had an identified intraoperative CSF leak, 250
(92.9%) of them had fluorescein‑stained CSF identified
during the procedure and were labeled as true positives.
The remaining 19 (7.1%) patients had clear, unstained CSF
that was identified and were categorized as false negatives.
There were no false positives. This data generated the
sensitivity and specificity of low‑dose intrathecal fluorescein
to detect an intraoperative CSF leak to be 92.9% and 100%,
respectively. An overall total of 7 (1.7%) patients developed
a postoperative CSF leak within the 1st month. All of these
patients were true positives. Lesion type, approach corridor,
reconstruction method, and operative time were not risk
factors predictive of a postoperative CSF leak.

have observed that good pulsation of the reconstruction
at the conclusion of surgery usually confirms a watertight
closure and may provide an additional objective data
point to ensure good coverage of an iatrogenic known
dural defect. A randomized controlled study would be
needed to provide stronger conclusions on the utility of
routine intrathecal fluorescein.
Summary Written by: Anand V Germanwala, MD

SPINAL INTRAARTERIAL CHEMOTHERAPY:
INTERIM RESULTS OF A PHASE I CLINICAL
TRIAL[1]
Study Question: Is spinal intraarterial chemotherapy
(SIAC) safe and feasible for the treatment of metastatic
spinal epidural tumors in patients who have exhausted
standard therapeutic options?

Perspective: While retrospective, this well‑organized study
underscores the significance of intraoperative identification
of a CSF leak during endoscopic endonasal skull base
surgery. The authors note that intrathecal fluorescein
can help identify intraoperative CSF leaks with high
sensitivity and specificity. The overall false negative rate of
4.5% was hypothesized to be due to arachnoidal scarring,
lumbar stenosis, inadequate time for circulation, and/
or unclear physiology. None of the false negative patients
developed postoperative CSF leaks, substantiating the
25 mg dosage of fluorescein. No side effects related to
intrathecal fluorescein were noted. Recognized limitations
of this study include lack of a randomized controlled study,
inability to identify patients with small, postoperative leaks
that spontaneously resolve, and absence of an objective
measurement tool to assess for intraoperative leaks.

Patsalides et al. reported the interim outcomes of an
ongoing single arm prospective Phase I clinical trial
investigating the role of SIAC for advanced metastatic
spinal tumors that are no longer candidates for resection
or radiotherapy. Patients older than 18 years of age with
metastatic spinal disease causing cord compression on
imaging disease causing cord compression on imaging
were included in the study. Determination of those who
are not candidates for resection or radiotherapy was made
based on prior consensus among radiation oncologists
and neurosurgeons. Those with severe cord compression
where the subarachnoid space was completely occluded
were excluded. In addition, patients with <3 months life
expectancy or have the same segmental arteries supplying
the spinal cord and the tumor on diagnostic angiography
were excluded. Nine patients with 7 different tumor types
underwent selective spinal angiography and received
19 IA treatments of melphalan, an alkylating agent.
After diagnostic angiography of segmental arteries at the
level of cord compression, including one level above and
below, the ventral branch of the segmental arteries were
occluded with coils to maximize chemotherapy delivery
along the dorsal branch supplying the tumor while
minimizing its delivery to adjacent healthy tissue.

Multiple other high‑volume institutions that perform
such surgery without routine fluorescein administration
report similar intraoperative and postoperative CSF
leak rates while avoiding the infrequent side effects
of fluorescein, dexamethasone, and diphenhydramine,
as well as the rare complications of accessing the
lumbar cistern via needle or catheter. In addition,
150 of the 419 patients in this article did not have an
intraoperative CSF leak, negating any potential benefit
from intrathecal fluorescein. We recognize the advantage
of intrathecal fluorescein and favor its judicious use to
help identify unclear leak sites in patients with suspected
spontaneous or traumatic CSF leaks. Furthermore, we

Melphalan was chosen based on its established and
promising IA use in a variety of other malignancies
including colorectal metastases to the liver and lung
metastases. Total injected dose was 16 mg/m2, representing
the recommended systemic dose. Patients were allowed
up to 3 SIAC procedures in 1 sitting, repeated up to ever
3 weeks. Patients were followed up with, at minimum,
one spinal magnetic resonance imaging (MRI) with
contrast at 4 weeks following SIAC to determine possible
complications and tumor control. Follow‑up ranged from
1 to 7 months. One patient experienced neutropenic
fevers, and no other adverse effects were noted. Only 4/9
patients received the planned 3 separate IA treatments.
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While tumor size was stable in 7 and decreased in 1,
disease progression was noted at spinal levels where SIAC
was not given.
Perspective: The authors report their experience thus far
in an ongoing Phase I trial utilizing SIAC for progressive
spinal metastasis with cord compression in patients
for which conventional therapies have failed. Although
advances in microsurgical technique and radiotherapy
have improved the rates of tumor control for patients
with metastatic spinal disease, there remains a subset of
patients that fail or are no long candidates for standard
therapies. For these patients, prognosis remains grim,
and innovative treatment modalities are essential,
as inevitable neurological deterioration secondary to
progressive cord compression will occur.
Selective IA delivery of chemotherapy offers a number
of pharmacokinetic advantages of maximizing local drug
concentration and minimizing systemic toxicity. While its
use in other malignancies has been reported, this is the first
report of its application in spinal metastasis. Early results
are promising, with only 1 incidence of myelosuppression
and neutropenic fevers. In addition, tumor control at
the levels treated was seen in all but 1 patient. Indeed,
efficacy should be interpreted with caution due to short
length of MRI follow‑up due to advance stage of disease
in patients. Moreover, the optimization of SIAC for the
treatment of these metastatic lesions requires further
investigation. While melphalan has demonstrated efficacy
by IA route in other cancers, clinical response is likely
tumor‑dependent, and the present study included a variety
of metastatic tumor types. Optimal patient selection
to minimize complications and identification of ideal
chemotherapeutic agents for differing tumor types requires
further elaboration from larger data sets. However, despite
the small study size and limited follow‑up, the study
highlights SIAC as a novel therapeutic that can benefit
patients who have exhausted their therapeutic options.
Summary Written by: Winward Choy, BA and Zachary A
Smith, MD

FAREWELL TO OLIGOASTROCYTOMA:
IN SITU MOLECULAR GENETICS
FAVOR CLASSIFICATION AS EITHER
OLIGODENDROGLIOMA OR
ASTROCYTOMA[3]
Study Question: What is the impact of molecular
genetics in glioma classification and the subsequent
treatment of these patients?
The authors evaluated 43 oligoastrocytoma specimens
with the presence of the IDH1 R132H mutation as well
as at least 1 cm2 of intermingled histology. The specimens
were then evaluated with immunohistochemistry for

the ATRX and p53 mutations. Fluorescence in situ
hybridization was used for analysis of the 1p/19q
co‑deletion. The authors confirmed that all tumors cells
with p53 or ATRX mutation or 1p/19q co‑deletion also
stained for the IDH1 R132H mutation. The authors
identified 30 cases with the IDH1 R132H exclusively in
histology consistent with oligodendroglioma. This portion
of the tumor displayed the 1p/19q co‑deletion. In contrast,
the “astrocytic” portion of these specimens was devoid of
the ISH1R132H, p53, or ATRX mutations or 1p/19q loss.
This “astrocytic” portion was consequently inferred to be
reactive. The authors also identified 11 cases with both
ATRX and p53 mutations without 1p/19q co‑deletion,
indicative of an astrocytoma despite some areas of
oligodendroglial histology. One case displayed 1p/19q
co‑deletion in both the astrocytic and oligodendroglial
portions without the ATRX or p53 mutations and was
interpreted as an oligodendroglioma. The last specimen
was resected from a patient with a prior history of
irradiation and displayed the ATRX and p53 mutations
as well as the 1p/19q co‑deletion in both the astrocytic
and oligodendroglial portions of the specimen. Of note,
radiation has previously been associated with p53 and
ATRX mutations, which may explain the findings in this
specimen.
Perspective: The authors of this study aim to evaluate
the diagnosis of oligoastrocytoma via in situ molecular
genetics. Recent literature establishes that pure
astrocytomas display mutations in both ATRX and
TP53, whereas true oligodendrogliomas display 1p/19q
co‑deletion. Oligodendroglioma patients typically display
a significantly longer overall survival as compared
to patients with astrocytoma. This difference partly
correlates with response to chemotherapy, as seen in
patients with the 1p/19q co‑deletion. The diagnosis of
oligoastrocytoma was previously defined by the WHO
as a mixture of histologic features of astrocytoma and
oligodendroglioma on histology. However, no guidelines
exist on the minimal percentage of each subtype
complicated by the typically minor total tumor fraction
provided intraoperatively.
This study provides data that delineates between the
diagnosis of oligodendrogliomas and astrocytoma beyond
histology alone. Molecular genetics will serve as a key
component to the diagnosis of gliomas. Recent data from
such trials as Radiation Therapy Oncology Group 9802
indicate that patients with WHO Grade II gliomas may
benefit from chemotherapy and/or radiation. As upcoming
trials look to study the efficacy of temodar versus
procarbazine, lomustine, and vincristine chemotherapy in
lower grade gliomas, differences in outcome in astrocytic
versus oligodendroglial subtypes using the molecular
genetic distinctions as described in this study may help
distinguish the true role of these treatment regimens. In
S717

SNI: Neurosurgery Concepts 2016,Vol 7: Suppl 27 - A Supplement to Surgical Neurology International

addition, the use of molecular genetics will certainly play
a key role in differentiating Grade IV from lower grade
gliomas, which will impact enrollment into future clinical
trials.
Summary Written by: Jonathan H Sherman, MD

PRENATAL MYELOMENINGOCELE CLOSURE
AND THE NEED FOR CEREBROSPINAL
FLUID SHUNT PLACEMENT [4]
Study Question: What are the 1 year outcomes from
the Management of Myelomeningocele Study (MOMS)
trial? Are specific risk factors associated with benefit from
prenatal surgery?
MOMS was a multicenter randomized trial comparing
both safety and efficacy of prenatal and postnatal closure
of myelomeningocele (MMC).[1] Pregnant women with a
fetus prenatally diagnosed with MMC between 19 and
25 weeks of gestation were randomized at one of the
3 maternal‑fetal surgery centers to either prenatal or
postnatal surgical MMC repair. In the trial, the primary
outcome was defined as a composite of fetal loss or
any of the following: Infant death, cerebrospinal fluid
(CSF) shunt placement, or meeting prespecified criteria
for shunt placement before 1 year of age. In this paper,
the authors examine primary outcome, actual shunt
placement, and shunt revision surgery rates for patients
who underwent prenatal and postnatal repair. The
criteria for placement of CSF shunt were re‑examined.
The authors noted that during almost a decade of
recruitment, the management of pediatric hydrocephalus
had changed. In the published cohort, about one‑fourth
of patients in the prenatal surgery group and one‑tenth
of patients in the postnatal surgery group met the criteria
for CSF shunt placement, but did not have actual CSF
shunt placement. This observation led the authors to
conduct this current investigation (it is important to
note there was a blinded adjudication process for the
evaluation of hydrocephalus in the MOMS trial). The
authors also speculate whether it is possible to identify
which fetuses are likely or unlikely to benefit from
prenatal surgery. Logistic regression was used to examine
for interactions between the type of MMC repair surgery
and prenatal risk factors for shunt placement. These
included MMC lesion level, gestational age, amount of
hindbrain herniation, and ventricle size.
The MOMS trial was stopped early with demonstrated
efficacy of prenatal surgery when 158 of 183 pregnancies
were reported. Here, the authors report on results from
183 pregnancies: 91 women with prenatal surgery and
92 women randomized to postnatal surgery. Using the
definition above, the primary outcome occurred in 73% of
infants in the prenatal surgery group and 98% of infants in
the postnatal surgery group (P < 0.0001). Actual shunting
S718

rates were 44% and 84%, respectively (P < 0.0001). For
the decisions of actual shunt placement, it appeared that
treating pediatric neurosurgeons incorporated evaluation
of clinical signs of increased intracranial pressure
rather than relying on progressive ventriculomegaly on
radiographic findings alone. The authors revised the
most commonly met criteria to include overt clinical
signs of increased intracranial pressure, such as split
cranial sutures, bulging fontanelle, or sun‑setting
eyes, in addition to increasing head circumference or
hydrocephalus. Using these proposed modified criteria,
only three patients in each group met criteria, but did
not undergo actual shunt placement. For the revised
composite outcome, there was a difference between
the prenatal and postnatal surgery groups: 49.5% versus
87.0% (P < 0.0001). In the prenatal surgery group, 20%
of those with ventricle size <10 mm at initial screening,
45.2% of those with ventricle size of 10–15 mm, and
79.0% of those with ventricle size ≥15 mm received a
shunt. In the postnatal group, 79.4%, 86.0%, and 87.5%,
respectively, underwent CSF shunt placement (P = 0.02).
Only ventricle size was significantly associated with CSF
shunt placement or with the revised composite outcome,
with odds ratios of 1.46 (95% confidence interval [CI]
1.20–1.79) and 1.57 (95% CI 1.26–1.97), respectively.
Lesion level, gestational age, sex, and degree of hindbrain
herniation were not significantly associated with receiving
CSF shunt on multivariable logistic regression.
Perspective: This study reported on updated results
from an important randomized trial of prenatal versus
postnatal surgery for repair of MMC. Of the prenatal
risk factors that may predict the future need for CSF
shunt placement, only ventricle size was significantly
associated with the need for shunting. Larger ventricles
at initial screening are associated with increased need for
CSF shunting among those in the prenatal surgery group.
From this knowledge, the authors conclude that during
prenatal counseling for parents, care should be exercised
in predicting beneficial effects on the need for shunting
after undergoing fetal surgery for MMC in patients with
ventricles 15 mm or larger at the time of initial screening;
prenatal surgery does not appear to improve outcome in
this group. The revised criteria proposed in this study
may be useful as guidelines for treating hydrocephalus
in this group. This study found that pediatric
neurosurgeons are more likely to rely on clinical signs
of increased intracranial pressure by assessment of the
anterior fontanelle or cranial sutures than on traditional
radiological signs of ventriculomegaly or growth of head
circumference for treating hydrocephalus. This finding
is in keeping with the body of contemporary pediatric
neurosurgery literature. Postnatal criteria of surgical
intervention for hydrocephalus have been evolving, both
with the practice of permissive ventriculomegaly and
with the current interest in and evaluation of endoscopic
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third ventriculostomy/choroid plexus coagulation as an
attractive alternative to CSF shunting in MMC patients.
Overall, there appears to be a trend toward reduction
in CSF shunting rates for patients with MMC in the
past decade. The field is in evolution, and our new
understanding is yet to be completely defined.
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